TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Hepatology Forum · 2026 · 7 (3) · 177-214
DOI: 10.14744/hf.2026.44190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Forum, 2026. Verfasst von Yusuf Yilmaz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and represents a major and growing public health challenge in Türkiye. This guidance provides an updated, clinically oriented overview of the definition, epidemiology, screening, diagnosis, risk stratification, and management of MASLD, with particular emphasis on evolving nomenclature, non-invasive diagnostic pathways, and current treatment strategies. The document addresses the full clinical spectrum of disease, from steatosis and metabolic dysfunction-associated steatohepatitis (MASH) to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation. The guidance also incorporates evidence and practice considerations relevant to the Turkish population, including local epidemiology, resource availability, and implementation challenges in real-world care. Finally, areas of uncertainty and evidence gaps are highlighted to support future research and locally relevant policy development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye.
- Dijitalpark Teknokent, İstanbul, Türkiye.
- Department of Gastroenterology, University of Health Sciences, Istanbul Umraniye Training and Research Hospital, Istanbul, Türkiye.
- The Roger Williams Institute of Liver Studies, King's College Hospital, London, UK.
- Department of Medicine, University Hospital Knappschaft Kliniken Bochum, Ruhr University Bochum, Bochum, Germany.
- Department of Gastroenterology, Ankara University Faculty of Medicine, Ankara, Türkiye.
Zitieren
APA
Yilmaz, Y., Adali, G., Ergenc, I., Kaya, E., Gokce, D. T., Keklikkiran, C., Zeybel, M., Us, G. D., Degertekin, B., Idilman, R., Turkish Association for the Study of the Liver (TASL) Obesity Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Special Interest Group (SIG), Akarca, U. S., Karasu, Z., Kaymakoglu, S., Tozun, N., & Uygun, A. (2026). TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD). Hepatology Forum, 7(3), 177-214. https://doi.org/10.14744/hf.2026.44190
Vancouver
Yilmaz Y, Adali G, Ergenc I, Kaya E, Gokce DT, Keklikkiran C, et al. TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD). Hepatology Forum. 2026;7(3):177-214. doi:10.14744/hf.2026.44190
BibTeX
@article{Yilmaz2026,
author = {Yilmaz, Yusuf and Adali, Gupse and Ergenc, Ilkay and Kaya, Eda and Gokce, Dilara Turan and Keklikkiran, Caglayan and Zeybel, Mujdat and Us, Gediz Dogay and Degertekin, Bulent and Idilman, Ramazan and Turkish Association for the Study of the Liver (TASL) Obesity Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Special Interest Group (SIG), Turkish Association for the Study of the Liver (TASL) Obesity Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Special Interest Group (SIG) and Akarca, Ulus Salih and Karasu, Zeki and Kaymakoglu, Sabahattin and Tozun, Nurdan and Uygun, Ahmet},
title = {TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD)},
journal = {Hepatology Forum},
year = {2026},
volume = {7},
number = {3},
pages = {177--214},
doi = {10.14744/hf.2026.44190}
}
EUVIMED